New Drug may Provide Relief Against Migraine

New Drug may Provide Relief Against Migraine

Health In Focus
RSS Email Print This Page Comment bookmark
Font : A-A+

  • When all other treatments for migraine have failed, patients may find relief with a new drug called erenumab.
  • Erenumab is a monoclonal antibody, which blocks pain signals by targeting a receptor for a peptide that transmits migraine pain signals.
  • In a third of the patients, erenumab reduced the average number of monthly migraine headaches by more than 50%.
While there are treatment options for migraine, they often fail to work for patients. However, a new drug called erenumab may provide relief for patients for whom all other treatment options have failed, according to the preliminary study results presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles.

Migraine and Erenumab

Migraine is a common neurological disorder that is often difficult to treat. It can cause severe throbbing pain or a pulsing sensation, on one or both sides of the head. A migraine may also be accompanied by nausea, vomiting, and extreme sensitivity to light and sound. It can last for a few hours to a few days and severely affects the quality of life.
New Drug may Provide Relief Against Migraine

The drug tested in this study, Erenumab, is a monoclonal antibody that blocks pain signals by targeting a receptor for a peptide that transmits migraine pain signals called calcitonin gene-related peptide (CGRP). Erenumab binds to this receptor which CGRP would normally bind to and thereby blocks pain signals.

Study overview

The study included 246 people who had episodic migraine. The participants were given injections of either 140 milligrams of erenumab or a placebo once a month for a three month period. Thirty nine percent of the study population had been treated unsuccessfully with two other medications, thirty eight percent with three medications and twenty three percent with four medications. The participants on average, experienced nine migraine headaches a month.

"The people we included in our study were considered more difficult to treat, meaning that up to four other preventative treatments hadn't worked for them," said study author Uwe Reuter, MD, of The Charité - University Medicine Berlin in Germany. "Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50 percent for nearly a third of study participants. That reduction in migraine headache frequency can greatly improve a person's quality of life."

Study findings

  • After the three month treatment period, patients treated with erenumab were three times more likely to have reduced their migraine days by 50% or more than those treated with placebo.
  • Thirty percent of the people treated with erenumab had half the number of headaches compared to 14% of patients treated with placebo.
  • Patients treated with erenumab had a greater average reduction in the number of days they had headaches and the number of days they needed to take drugs to stop the migraines.
  • The safety and tolerability of erenumab were similar to placebo and none of the participants taking erenumab stopped treatment due to side effects.
"Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief," said Reuter. "More research is now needed to understand who is most likely to benefit from this new treatment."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Drug Toxicity Migraine Clinical Trials - Different Phases of the trial Signature Drug Toxicity Headache / Cephalgia Drugs Banned in India Headache Symptom Evaluation Retinal Migraine / Ocular Migraine Menstrual Migraine 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive